

One-Pot Synthesis of 2,4-Benzodiazepin-1-ones Using Benzotriazole Methodology

Alan R. Katritzky,* Satheesh K. Nair,
Valerie Rodriguez-Garcia, and Yong-Jiang Xu

Center for Heterocyclic Compounds, Department of
Chemistry, University of Florida,
Gainesville, Florida 32611-7200


Katritzky@chem.ufl.edu

Received May 6, 2002

Abstract: 2, 4-Benzodiazepin-1-ones were prepared in moderate to good yields by reaction of bis(benzotriazolylmethyl)amines with ortho-metalated N-substituted benzamides.

Many benzodiazepines display potent pharmacological activity. 1,4-Benzodiazepine-2,5-diones are platelet glycoprotein antagonists IIB–IIIa¹ and anticonvulsant agents.² 1,4-Benzodiazepine is a “privileged scaffold”³ with exceptional ability to mimic natural ligands. Additionally, many alkaloids are benzodiazepines.⁴ Synthetic interest has so far focused on 1,4-benzodiazepines,⁵ 1,5-benzodiazepines,⁶ and 2,3-benzodiazepines.⁷ Published synthetic routes to 2,4-benzodiazepines are scarce: 2,4-benzodiazepin-1,3-diones are formed by the palladium-catalyzed intramolecular cyclization of 1-butyl-1(o-iodobenzyl)-3-phenylurea,⁸ and there is one reported synthesis of 2,3-benzodiazepin-1-one from 2-[(dimethylamino)methyl]benzamide.⁹ We now describe a one-pot

SCHEME 1



synthesis of 2, 4-benzodiazepin-1-ones utilizing benzotriazole strategy.

N,N-Bis(benzotriazolylmethyl)alkylamines, easily prepared from primary amines, benzotriazole, and formaldehyde,¹⁰ are useful for the synthesis of julolidines,¹¹ 1,3-oxazolidines,¹² and 3-aryl pyrrolidines.¹³ Bis(benzotriazolylmethyl)amines are nitrogen-centered 1,3-dication synthons as is well exemplified in their application in the synthesis of substituted piperidines.¹⁴ We now show that this concept combined with an ortho metalation process can lead to 2,4-benzodiazepin-1-ones.

Results and Discussions

N-Alkylbenzamides generate dianions in orthometalation chemistry.¹⁵ When *N*-methylbenzamide **1a** was treated with butyllithium at -78°C in diethyl ether and reacted with bisbenzotriazolyl derivative **3a**, only the starting materials were recovered after workup (Scheme 1). However, addition of ZnBr_2 to the reaction mixture caused the reaction to take place as desired. After addition of **3a**, the reaction mixture was stirred overnight at room temperature. Aqueous workup and isolation yielded the benzodiazepin-1-one **4a** in 22% yield. The yield of **4a** was improved to 64% by conducting the reaction at -10°C . The ZnBr_2 acts in this reaction as a Lewis acid; it activates the benzotriazole and thereby expedites the C–N bond scission. This is characteristic of benzotriazole chemistry.¹⁴ Bis(benzotriazolylmethyl)alkylamines prepared from other primary amines also reacted similarly under the modified conditions giving the corresponding 2,4-benzodiazepin-1-one in good to moderate yields. The results are summarized in

(1) McDowell, R. S.; Blackburn, B. K.; Gadek, T. R.; McGee, L. R.; Rawson, T.; Reynolds, M. E.; Robarge, K. D.; Somers, T. C.; Thorsett, E. D.; Tischler, M.; Webb, R. R., II; Venuti, M. C. *J. Am. Chem. Soc.* **1994**, *116*, 5077.

(2) Cho, N. S.; Song, K. Y.; Parkanyi, C. *J. Heterocycl. Chem.* **1989**, *26*, 1807.

(3) Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S.; Chang, R. S. L.; Lotti, V. J.; Cerino, D. J.; Chen, T. B.; Kling, P. J.; Kunkel, K. A.; Springer, J. P.; Hirshfield, J. *J. Med. Chem.* **1988**, *31*, 2235.

(4) Witt, A.; Bergman, J. *J. Org. Chem.* **2001**, *66*, 2784.

(5) (a) Damayanthi, Y.; Reddy, B. S. P.; Lown, J. W. *J. Org. Chem.* **1999**, *64*, 290. (b) Wang, T.; Lui, A. S.; Cloudsdale, I. S. *Org. Lett.* **1999**, *1*, 1835. (c) Juaristi, E.; Leon-Romo, J. L.; Ramirez-Quiros, Y. *J. Org. Chem.* **1999**, *64*, 2914. (d) Boojamra, C. G.; Burow, K. M.; Thompson, L. A.; Ellman, J. A. *J. Org. Chem.* **1997**, *62*, 1240. (e) Hulme, C.; Peng, J.; Tang, S.-Y.; Burns, C. J.; Morize, L.; Labaudiniere, R. *J. Org. Chem.* **1998**, *63*, 8021.

(6) (a) Ursini, A.; Capelli, A. M.; Carr, R. A. E.; Cassara, P.; Corsi, M.; Curcuruto, O.; Curotto, G.; Cin, M. D.; Davalli, S.; Donati, D.; Feriani, A.; Finch, H.; Finizia, G.; Gaviraghi, G.; Marien, M.; Pentasuglia, G.; Polinelli, S.; Ratti, E.; Reggiani, A.; Tarzia, G.; Tedesco, G.; Tranquillini, M. E.; Trist, D. G.; Van Amsterdam, F. T. M. *J. Med. Chem.* **2000**, *43*, 3596. (b) Chuang, T.-H.; Sharpless, K. B. *Org. Lett.* **2000**, *2*, 3555.

(7) (a) Grasso, S.; De Sarro, G.; De Sarro, A.; Micale, N.; Zappala, M.; Puia, G.; Baraldi, M.; De Micheli, C. *J. Med. Chem.* **1999**, *42*, 4414. (b) Zappala, M.; Gitto, R.; Bevacqua, F.; Quartarone, S.; Chimiri, A.; Rizzo, M.; De Sarro, G.; De Sarro, A. *J. Med. Chem.* **2000**, *43*, 4834.

(8) Bocelli, G.; Catellani, M.; Cugini, F.; Ferraccioli, R. *Tetrahedron Lett.* **1999**, *40*, 2623.

(9) Mohrle, H.; Lessel, J. *Arch. Pharm.* **1991**, *324*, 367.

(10) (a) Katritzky, A. R.; Rachwal, S.; Rachwal, B. *J. Chem. Soc., Perkin Trans. 1* **1987**, 799. (b) Katritzky, A. R.; Rachwal, S.; Wu, J. *Can. J. Chem.* **1990**, *68*, 446.

(11) Katritzky, A. R.; Rachwal, B.; Rachwal, S. *J. Org. Chem.* **1996**, *61*, 3117.

(12) Katritzky, A. R.; Feng, D.; Qi, M. *Tetrahedron Lett.* **1998**, *39*, 6835.

(13) Katritzky, A. R.; Feng, Y.; Qi, M.; Feng, D. *Heterocycles* **1998**, *48*, 2535.

(14) Katritzky, A. R.; Luo, Z.; Cui, X.-L. *J. Org. Chem.* **1999**, *64*, 3328.

(15) Snieckus, V. *Chem. Rev.* **1990**, *90*, 879.

TABLE 1. 2, 4-Benzodiazepine-1-ones Prepared

entry	R	R ¹	yield
4a	CH ₃	C ₄ H ₉	64
4b	^t Bu	C ₄ H ₉	82
4c	C ₆ H ₅	phenethyl	53
4d	<i>p</i> Cl-C ₆ H ₄	C ₄ H ₉	57
4e	C ₆ H ₅	C ₄ H ₉	47
4f	^t Bu	phenethyl	36
4g	C ₆ H ₅	cyclohexyl	74
4h	CH ₃	cyclohexyl	57

Table 1. A variety of *N*-alkyl- and *N*-aryl-benzamides were also used for the generation of ortholithiated benzamides.

In conclusion, we describe a one-pot synthesis of 2,4-benzodiazepin-1-ones starting from easily affordable starting materials and utilizing simple chemistry.

Experimental Section

Melting points were determined using a hot-stage microscope and are uncorrected. ¹H (300 MHz) and ¹³C (75 MHz) NMR spectra were recorded on a 300 MHz NMR spectrometer in chloroform-*d* solution. Column chromatography was performed on silica gel (300–400 mesh). THF was distilled from sodium-benzophenone ketal prior to use. All the reactions were performed under a nitrogen atmosphere and in flame-dried glasswares.

General Procedure for the Preparation of 2,4-Benzodiazepin-1-ones. The *N*-substituted benzamide (3 mmol) was dissolved in THF (30 mL). *n*-BuLi (6.6 mmol) was added dropwise at –10 °C. The mixture was gradually warmed to 0 °C and stirred for 30 min. After the mixture was cooled to –10 °C, ZnBr₂ (7 mmol) was added to the mixture followed by the addition of the *N,N*-bis(benzotriazolyl)amine (3 mmol). The resulting mixture was allowed to warm to room temperature and stirred for 24 h. The reaction was quenched with 2 M NaOH, and the mixture was washed with brine and extracted with EtOAc. Column chromatography (Al₂O₃, from 10/1 to 6/1 hexanes/EtOAc) afforded the analytically pure benzodiazepines.

2-Methyl-4-butyl-2,3,4,5-tetrahydro-1H-2,4-benzodiazepin-1-one 4a: yellow oil (64%); ¹H NMR δ 7.77–7.74 (m, 1H), 7.44–7.40 (m, 2H), 7.26–7.24 (m, 1H), 4.09 (s, 2H), 3.64 (s, 2H), 3.27 (s, 3H), 2.71 (t, *J* = 7.3 Hz, 2H), 1.62–1.56 (m, 2H), 1.44–1.37 (m, 2H), 0.97 (t, *J* = 7.4 Hz, 3H); ¹³C NMR δ 171.1, 136.5, 134.4, 131.1, 129.0, 128.5, 128.2, 68.1, 55.2(2), 36.3, 30.1, 20.4, 13.9; HRMS (FAB) calcd for C₁₄H₂₀N₂O (M + H) 233.1654, found 233.1629.

2-(*tert*-Butyl)-4-butyl-2,3,4,5-tetrahydro-1H-2,4-benzodiazepin-1-one 4b: isolated as a colorless oil (82%); ¹H NMR δ 7.76 (dd, *J* = 6.7, 2.2 Hz, 1H), 7.43–7.37 (m, 2H), 7.10 (dd, *J* = 6.5, 1.9 Hz, 1H), 3.78 (s, 4H), 2.31 (t, *J* = 7.0 Hz, 2H), 1.59 (s, 9H), 1.51–1.46 (m, 2H), 1.40–1.35 (m, 2H), 0.93 (t, *J* = 7.2 Hz, 3H); ¹³C NMR δ 172.1, 138.3, 131.5, 130.8, 128.8, 128.2, 128.0, 63.2, 57.1, 53.6, 51.8, 30.1, 28.7, 20.5, 14.0. Anal. Calcd for C₁₇H₂₆N₂O: C, 74.41; H, 9.55; N, 10.21. Found: C, 74.35; H, 10.06; N, 10.40.

2-Phenyl-4-phenylethyl-2,3,4,5-tetrahydro-1H-2,4-benzodiazepin-1-one 4c: isolated as a yellow oil (53%); ¹H NMR δ 7.85 (dd, *J* = 6.9, 1.6 Hz, 1H), 7.50–7.40 (m, 6H), 7.39–7.17 (m, 5H), 6.98 (d, *J* = 6.7 Hz, 2H), 4.56 (s, 2H), 3.92 (s, 2H), 2.84–2.79 (m, 2H), 2.74–2.69 (m, 2H); ¹³C NMR δ 170.7, 143.2, 139.4, 136.3, 134.0, 131.6, 129.3, 129.1, 129.1, 128.6, 128.4, 126.7, 126.2, 126.1, 68.1, 56.6, 55.3, 34.6. Anal. Calcd for C₂₃H₂₂N₂O: C, 80.67; H, 6.48; N, 8.18. Found: C, 80.53; H, 6.46; N, 8.19.

2-(4-Chlorophenyl)-4-butyl-2,3,4,5-tetrahydro-1H-2,4-benzodiazepin-1-one 4d: isolated as a colorless oil (57%); ¹H NMR δ 7.52–7.39 (m, 6H), 7.33–7.26 (m, 2H), 4.65 (s, 2H), 4.00 (s, 2H), 2.55 (t, *J* = 7.3 Hz, 2H), 1.40–1.24 (m, 4H), 0.83 (t, *J* = 7.3 Hz, 3H); ¹³C NMR δ 171.0, 136.0, 135.6, 130.9, 129.6, 128.6, 128.4, 127.5, 126.7, 126.3, 125.3, 66.0, 53.0, 52.3, 29.7, 20.3, 13.9. Anal. Calcd for C₁₉H₂₁ClN₂O: C, 69.4; H, 6.74; N, 8.52. Found: C, 69.3; H, 6.57; N, 8.52.

2-Phenyl-4-butyl-2,3,4,5-tetrahydro-1H-2,4-benzodiazepin-1-one 4e: isolated as a yellow oil (47%); ¹H NMR δ 7.84 (dd, *J* = 6.9, 1.9 Hz, 1H), 7.52–7.39 (m, 6H), 7.33–7.26 (m, 2H), 4.50 (s, 2H), 3.86 (s, 2H), 2.57 (t, *J* = 7.3 Hz, 2H), 1.43–1.38 (m, 2H), 1.29–1.22 (m, 2H), 0.83 (t, *J* = 7.3 Hz, 3H); ¹³C NMR δ 170.8, 143.3, 136.4, 134.2, 131.6, 129.3, 129.1, 129.0, 128.5, 126.6, 126.2, 68.6, 55.2, 54.7, 29.8, 20.3, 13.8. Anal. Calcd for C₁₉H₂₂N₂O: C, 77.52; H, 7.53; N, 9.52. Found: C, 76.57; H, 8.64; N, 9.43.

2-(*tert*-Butyl)-4-phenylethyl-2,3,4,5-tetrahydro-1H-2,4-benzodiazepin-1-one 4f: isolated as a yellow oil (36%); ¹H NMR δ 7.78–7.75 (m, 1H), 7.41–7.37 (m, 2H), 7.31–7.25 (m, 2H), 7.22–7.18 (m, 3H), 7.11–7.08 (m, 1H), 3.84 (s, 2H), 3.82 (s, 2H), 2.82 (t, *J* = 7.0 Hz, 2H), 2.58 (t, *J* = 7.0 Hz, 2H), 1.56 (s, 3H); ¹³C NMR δ 172.1, 139.9, 138.2, 131.3, 130.9, 128.7, 128.6, 128.4, 128.2, 128.1, 126.2, 63.1, 57.1, 54.0, 53.7, 34.8, 28.6. Anal. Calcd for C₂₁H₂₆N₂O: C, 78.22; H, 8.13; N, 8.69. Found: C, 78.09; H, 8.19; N, 8.72.

2-Phenyl-4-cyclohexyl-2,3,4,5-tetrahydro-1H-2,4-benzodiazepin-1-one 4g: isolated as colorless crystals (EtOAc/hexane), 74%, mp 102–103 °C; ¹H NMR δ 7.98–7.81 (m, 1H), 7.58–7.25 (m, 8H), 4.62 (s, 2H), 3.96 (s, 2H), 2.55–2.40 (m, 1H), 1.90–1.45 (m, 6H), 1.20–1.05 (m, 4H); ¹³C NMR δ 170.8, 142.6, 136.3, 134.9, 131.7, 129.3, 129.2, 129.0, 128.4, 126.6, 126.3, 64.8, 60.5, 52.8, 31.1, 25.8, 25.0. Anal. Calcd for C₂₁H₂₄N₂O: C, 78.71; H, 7.55; N, 8.74. Found: C, 76.01; H, 7.55; N, 7.96.

2-Methyl-4-cyclohexyl-2,3,4,5-tetrahydro-1H-2,4-benzodiazepin-1-one 4h: isolated as colorless liquid (57%); ¹H NMR δ 7.77–7.75 (m, 1H), 7.46–7.39 (m, 2H), 7.25–7.37 (m, 1H), 4.21 (s, 2H), 3.75 (s, 2H), 3.24 (s, 3H), 2.65–2.55 (m, 1H), 2.17–2.07 (m, 2H), 1.90–1.78 (m, 2H), 1.38–1.21 (m, 6H); ¹³C NMR δ 171.2, 136.4, 135.0, 131.3, 129.2, 128.4, 128.2, 64.4, 60.7, 52.4, 35.6, 31.3, 25.9, 25.3. Anal. Calcd for C₁₆H₂₂N₂O: C, 74.38; H, 8.58; N, 10.84. Found: C, 72.21; H, 9.75; N, 10.35.

Acknowledgment. We thank Alliance for Graduate Education and the Professoriate for a research fellowship (to V.R.-G.)

JO0203185